Home
Reels
Groups
Pages
See More
Groups Pages Events Blogs Jobs Forums
Sign In Sign Up
Day Mode
Healthcare

Intravenous Immunoglobulin (IVIg) Market: A Comprehensive Overview

The Intravenous Immunoglobulin (IVIg) Market has witnessed substantial growth driven by rising prevalence of immunodeficiency disorders and autoimmune diseases globally. This biologic therapy derived from pooled human plasma provides passive immunity for patients with compromised immune systems. Healthcare providers increasingly rely on IVIg therapy for treating primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.
The Intravenous Immunoglobulin (IVIg) Market continues expanding due to growing geriatric populations and increasing off-label indications. Pharmaceutical companies invest in plasma collection infrastructure and manufacturing capacity expansion. Regulatory approvals for new indications and improved safety profiles drive clinical adoption across hematology, neurology, and immunology specialties.

FAQ

Q: What drives growth in the IVIg market? A: Rising immunodeficiency prevalence, expanding indications, aging populations, and improved plasma collection infrastructure.
Q: Which regions lead this market? A: North America and Europe dominate due to established plasma collection networks and reimbursement frameworks.
Q: What are primary applications? A: Primary immunodeficiency, CIDP, multifocal motor neuropathy, myasthenia gravis, and dermatomyositis.
#Intravenous_Immunoglobulin_(IVIg)_Market
Please log in to like, share and comment!
Categories
Read More
Lukoon https://lukoon.com